Share this article
Share this article
COLLEGE STATION, Texas, May 12, 2021 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio) today announced that the Board of Directors has appointed Yun Jeong Song, MD, as the company s new Chief Executive Officer (CEO) to continue its expansion as a CDMO supporting the global cell and gene therapy industry. Dr. Song joined the company effective April 1
st, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. Dr. Song succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.
Matica Biotechnology GMP Facility (College Station TX, USA)
Dr. Song s background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.
Texas
United-states
Matica-bio
Samsung
Us-national-institutes-of-health
Matica-biotechnology-inc
Matica-biotechnology
Yun-jeong-song
Chief-executive-officer
Immuneoncia-therapeutics
College-station
Nc
Mar 8, 2021 10:23am
There s a ready market for viral vectors. Matica, a new CDMO and a subsidiary of South Korea-based CHA Biotech, will soon be poised to help meet the demand. (Harvard University)
A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines.
So it appears the timing is right for Matica Biotechnology, a developer and producer of viral vectors, to put down roots in the United States.
The brand-new CDMO has teamed up with Texas A&M University and its advanced manufacturing center and started work on a 25,000 square-foot viral vector plant near the university s College Station campus.
Boston
Massachusetts
United-states
Texas
San-francisco
California
Pharma-europe
Texasam-university
Matica-biotechnology
College-station
Pharma-marketing
Digital-pharma